Dendritic cells (DCs) are pivotal for the development of experimental autoimmune encephalomyelitis (EAE). However, the mechanisms by which they control disease remain to be determined. This study demonstrates that expression of CC chemokine receptor 4 (CCR4) by DCs is required for EAE induction. CCR4
Dendritic cells (DCs) are pivotal for the development of experimental autoimmune encephalomyelitis (EAE). However, the mechanisms by which they control disease remain to be determined. This study demonstrates that expression of CC chemokine receptor 4 (CCR4) by DCs is required for EAE induction. CCR4
−/− mice presented enhanced resistance to EAE associated with a reduction in IL-23 and GM-CSF expression in the CNS. Restoring CCR4 on myeloid cells in bone marrow chimeras or intracerebral microinjection of CCR4-competent DCs, but not macrophages, restored EAE in CCR4 −/− mice, indicating that CCR4 + DCs are cellular mediators of EAE development. Mechanistically, CCR4
−/− DCs were less efficient in GM-CSF and IL-23 production and also T H -17 maintenance. Intraspinal IL-23 reconstitution restored EAE in CCR4 −/− mice, whereas intracerebral inoculation using IL-23 −/− DCs or GM-CSF −/− DCs failed to induce disease. Thus, CCR4-dependent GM-CSF production in DCs required for IL-23 release in these cells is a major component in the development of EAE. Our study identified a unique role for CCR4 in regulating DC function in EAE, harboring therapeutic potential for the treatment of CNS autoimmunity by targeting CCR4 on this specific cell type.
chemokines | neuroinflammation M ultiple sclerosis (MS) is a chronic demyelinating disease of the human CNS (1) . Experimental autoimmune encephalomyelitis (EAE), the animal model of MS, is mediated by myelin-specific CD4 + T cells activated by professional antigenpresenting cells (APCs) in peripheral lymphoid tissues (2, 3) . In recent studies, both peripherally derived macrophages and DCs have been shown to present myelin antigens to invading autoreactive T cells in the CNS. This presentation initiates the recruitment of a second wave of leukocytes that damage the target organ via demyelination and axonal degeneration (4) (5) (6) (7) (8) . Understanding the mechanisms responsible for the recruitment of APCs to the CNS and their local function is essential for the development of therapeutic strategies targeting the effector phase and thereby controlling disease progression.
Chemokines and their G protein-coupled receptors are key regulators of leukocyte trafficking (9, 10) . The CC chemokine receptor 4 (CCR4) is the cognate receptor for the CC chemokines CCL17 and CCL22, and is expressed on functionally distinct subsets of T cells, including activated T cells, T H 2 cells, and Treg cells. CCR4 has also been found on platelets, NK cells, macrophages, and DCs (11) (12) (13) (14) (15) . DCs are important cellular sources for CCL17 and, in concert with macrophages, produce CCL22 during both homeostasis and inflammation (16, 17) . Different studies have suggested a critical role for CCR4 in the pathogenesis of EAE and MS. For example, elevated levels of the CCR4 ligands CCL17 or CCL22 have been found in the cerebrospinal fluid of MS patients (18) (19) (20) . CCL22 protein has been identified in CNS-infiltrating leukocytes and microglia of EAE-induced mice, and CCR4 is expressed by invading leukocyte subsets (21, 22) . However, it remained undefined which CCR4-expressing cell population mediates its role in the development of CNS autoimmunity. Expression of CCR4 on APCs suggests that APC-dependent mechanisms may be involved in EAE and MS.
Recent studies have demonstrated an impact of CCR4 and its ligands on basic APC functions. For example, the rapid binding of antigen-primed T cells to activated DCs was dependent on CCR4, and the duration of their cognate interaction correlated with increased CCL17 production by DCs (23, 24) . In addition, it was shown that CCL17 and CCR4 are implicated in facilitating a natural killer (NK) T cell-dependent way of licensing DCs for cross-priming (25) . Furthermore, the release of proinflammatory cytokines and chemokines upon Toll-like receptor (TLR) engagement has been associated with CCR4 regulation (26) .
In this study we sought to identify the essential CCR4-expressing cells mediating induction of EAE following myelin oligodendrocyte glycoprotein (MOG) peptide p35-55 immunization. We used a CCR4 knockout (CCR4 −/− ) mouse model, transfer of encephalitogenic lymphocytes, generation of mixed BM chimeras, and the stereotactic CNS inoculation of myeloid cells to decipher the CCR4-dependent underlying molecular mechanisms required for disease susceptibility. Our data identified CCR4 + DCs, rather than macrophages or T cells, as the key mediators in the development of EAE. We now show that GM-CSF-dependent IL-23 production in DCs was dependent on CCR4 expression in these cells and required for development of EAE. This functional role for CCR4 in the effector phase of disease points toward a unique strategy to inhibit CNS autoimmunity by targeting this chemokine receptor on DCs.
Results

CCR4 Deficiency in Hematopoietic Cells Confers EAE Resistance.
To determine the expression of CCR4 during EAE, C57BL/6 mice were immunized with MOG peptide (hereafter referred to as MOG) in complete Freund's adjuvant (CFA), and quantitative PCR analysis on CNS tissues was performed. At the peak of disease (day 17 after MOG immunization), CCR4 mRNA levels in the spinal cords were significantly increased; and they declined with the remission of neurological symptoms 34 d after immunization (Fig. 1A) . We found high CCR4 expression in CD4 + T cells isolated from the CNS, in contrast to low levels in CD11b + cells comprising macrophages/microglia and DCs (Fig. S1A) . In accordance, flow cytometry detected higher CCR4 surface levels on CD4 + T cells compared with myeloid-derived cells, both of which immigrated into the CNS as identified by high expression of the hematopoietic marker CD45 (Fig. S1B) (Fig. S2A) . In addition, CD4 + T cells isolated from CCR4 −/− mice at the priming phase (10 d after immunization) proliferated in response to MOG peptide to the same extent as WT CD4 + T cells (Fig. S2B) . Furthermore, percentages of IFN-γ-or IL-17 cytokine-producing T cells were equivalent in the spleens of CCR4 −/− and WT cells at the priming phase (Fig. S2C) .
We then asked whether MOG-reactive CD4 + T cells generated in CCR4 −/− mice were able to induce EAE upon adoptive transfer. To rule out a preferential role for CCR4 on T H -1 vs. −/− or WT T H -1 cells developed EAE with a comparable incidence and severity ( Fig.  2A) . Transfer of primed WT or CCR4 −/− T lymphocytes containing T H -17 cells induced only a mild EAE, but with equivalent clinical scores in WT recipients (Fig. S2F) . Thus, CCR4 is not required in a cell-autonomous way on MOG-reactive CD4 + T cells for the induction of EAE in naïve recipients.
Based on these results, we hypothesized that CCR4 does not play a role during the induction phase but rather during the effector stage of disease, i.e., within the CNS. Therefore, the course of EAE was compared in CCR4 −/− and WT animals following the adoptive transfer of MOG-reactive WT lymphocytes. WT mice developed severe clinical EAE (Fig. 2B ), whereas CCR4 −/− mice exhibited resistance to EAE. Thus, for disease susceptibility, CCR4 expression is not required on T cells, but on another cell type that promotes the inflammatory CNS response during the effector phase of EAE.
Myeloid-Derived CCR4 + Cells Are Required for Development of EAE.
We generated mixed BM-chimeric mice to test whether CCR4 expression on myeloid cells is required for EAE susceptibility. →WT) were resistant to EAE induction (Fig. 3A) . In striking contrast, mixed BM chimeras (CCR4 −/− + RAG-2 −/− →WT) exhibited a severe clinical manifestation of EAE after MOG immunization with equivalent incidence and severity as observed in controls (WT→WT). These findings indicate that EAE induction requires CCR4 expression on myeloid cells but not on T cells.
In a second set of mixed BM chimeric mice, the contribution of CCR4 expression on APCs vs. NK cells during EAE was investigated. For this, lethally irradiated WT recipients were reconstituted with CCR4 −/− BM cells mixed with BM cells from RAG-2 cγc double-knockout mice, which exhibit T-, B-, and NKcell deficiency ( (Fig. S4B) .
In a next step we used a stereotactic microinjection approach and investigated the capacity of CCR4-competent macrophages or DCs to mediate EAE after intracerebral inoculation. (Fig. 3B) . In striking contrast, CCR4 −/− mice developed an aggravated clinical manifestation of EAE with tail and hind paralysis if they were i.c. injected with CCR4 +/+ DCs (P < 0.01, days 11-17; for i.c. CCR4
+/+ DCs → CCR4 −/− mice vs. MOG-immunized controls). Moreover, the intracerebral inoculation using CCR4 −/− DCs did not lead to a significant altered EAE course in CCR4 −/− mice (Fig. S4C ). These findings demonstrate that CCR4-expressing DCs but not macrophages are required for EAE development, and further suggest that an inherent defect in CCR4 −/− DCs in providing the required milieu in the CNS for pathogenic T cells is the prevalent mechanism for EAE resistance in CCR4 −/− mice. −/− and WT BMDCs exhibited similar expression levels of MHC class II, CD40, CD80, and CD86 upon TLR ligand stimulation (Fig. S5A) . In addition, MOG-loaded splenic WT or CCR4 −/− DCs cultured with 2D2 T cells expressing a transgenic MOG-specific TCR (27) induced an equivalent proliferation in these cells (Fig. S5B) . Furthermore, MOG-reactive WT or CCR4
−/− CD4 + T cells exhibited equivalent percentages of IFN-γ-and IL-17-secreting cells, independent of whether they were rechallenged for 3 d with MOGloaded CCR4
−/− or WT BMDCs (Fig. S5C) . Overall, these experiments revealed no differences between CCR4 −/− and WT DCs in priming of naïve T cells. To evaluate the influence of CCR4 on DC migration in vivo, competitive transfer assays were performed. Fluorescently labeled CCR4 −/− BMDCs (carboxyfluorescein succinimidyl ester positive, CD45.2) were s.c. coinjected with BMDCs from C57BL/ 6 (CD45.1) mice in a 1:1 ratio into RAG-2 −/− (CD45.2) recipients. CCR4
−/− and C57BL/6 DCs were selectively detected in the draining lymph node (LN) in approximately equal percentages by flow cytometry after 48 h and not found in the nondraining LN, suggesting that CCR4 −/− DCs were capable of migrating from the peripheral tissue to the local LN (Fig. S5D) . Furthermore, equal numbers of immigrating CD45
high DCs were present in the CNS of CCR4 −/− mice compared with WT controls at day 10 after active immunization. This finding suggests that there is no major difference in CNS migration in CCR4 −/− mice at the onset of disease (Fig. S5E) . Overall, these experiments revealed no functional deficits of CCR4 −/− DCs in vitro or a reduced migratory capacity compared with WT DCs in vivo.
Reduced IL-23 Production and Maintenance of T H -17 Cells by CCR4
−/− DCs. We next examined the ability of DCs from WT vs. CCR4 −/− mice to produce cytokines implicated in EAE pathogenesis (28, 29) . BMDCs from WT vs. CCR4 −/− mice produced similar levels of TNF, IL-6, and IL-12 after TLR ligand stimulation (Fig. S6A) . However, BMDCs produced significantly less IL-23 in the absence of CCR4 ( Fig. 4A and Fig. S6A ). IL-23 was critically implicated in EAE development before by promoting T H -17 cells responses (30) (31) (32) . To examine the capability of CCR4 −/− DCs to maintain T H -17 cells in vitro, purified CD4 + WT T cells from MOG-immunized mice were cocultured with MOG-loaded CCR4 −/− DCs or WT DCs.
Equivalent percentages of T H -17 cells in MOG-reactive CD4 T cells were induced when rechallenged with MOG-loaded WT or CCR4
−/− DCs from day 1 to day 3 (Fig. S6B) . Though on day 4, percentages of IFN-γ-or IFN-γ/IL-17-producing CD4 + T cells were equal in these cultures, percentages of T H -17 cells were significantly reduced in the cultures with CCR4 −/− DCs but not WT DCs or phorbol 12-myristate 13-acetate (PMA) ionomycin (Fig. 4B and Fig. S6C ). These results indicated that CCR4 −/− DCs display a defect in IL-23 production and concomitantly are less efficient in the maintenance of T H -17 responses.
Next, IL-23 expression was investigated in the CNS of WT and CCR4 −/− mice at peak disease by ELISA, and revealed significant reduced cytokine levels in the CCR4 −/− CNS (Fig. 4C) . IL-23 release was also reduced in CNS-immigrating DCs in the CCR4 −/− CNS compared with WT controls, as verified by intracellular cytokine staining of CNS mononuclear cells isolated at this time point (Fig. 4D) .
To assess whether IL-23 production was required in DCs, we intracerebrally inoculated MOG-immunized CCR4 −/− mice with IL-23 −/− DCs (Fig. 4E) −/− mice, because the reconstitution with 500 ng IL-23 (but not 75 ng) induced severe disease in these mice (Fig. 4F) . Even CCR4 −/− mice injected with IL-23 intraventricularily or intraspinally-the latter an area where lesions would preferentially develop during MOG-EAE-developed an aggravated clinical form of disease (Fig. S6D) −/− DCs, respectively). Next, we evaluated whether the CCR4-CCL17/ CCL22 axis promotes IL-23 production by acting on upstream factors known previously to trigger IL-23 release in DCs, such as GM-CSF (33) . Indeed, treatment of DCs with CCL17/CCL22 led to GM-CSF production in CCR4-competent DCs, but not in CCR4 −/− DCs in vitro (Fig. 5A ). GM-CSF levels were significantly reduced in the CCR4 −/− CNS compared with WT controls at the peak of disease (Fig.  5B) . In addition, GM-CSF production was not detected by flow cytometry in immigrating DCs in the CCR4 −/− CNS in contrast to WT controls (Fig. 5C) . Also, levels of GM-CSF produced by mononuclear cells isolated from the CCR4 −/− CNS were significantly lower than those released from WT cells (Fig. 5D) . Furthermore, increasing the concentrations of GM-CSF in the DC cultures resulted in a dose-dependent increase in IL-23 production in LPS-stimulated CCR4-competent but not in CCR4-deficient DCs (Fig. 5E) . Accordingly, GM-CSF −/− DCs produced significantly lower levels of IL-23 compared with C57BL/6 controls, indicating that cell-autonomous processes are involved in GM-CSF-dependent IL-23 production in DCs (Fig.  5F ). To analyze if the reduced responsiveness of CCR4 −/− DCs toward GM-CSF stimulation was the result of a reduced presence of the receptor for GM-CSF on these cells, we analyzed mRNA or protein surface expression of csfr2b in CCR4 −/− DCs vs. WT DCs (Fig. S7) . mRNA expression and surface protein of csfr2b was present in equal amounts in CCR4 −/− DCs vs. WT DCs, suggesting that intracellular signal transduction pathways downstream of csfr2b may be modified in CCR4 −/− DCs (Fig.  S7) . We also found that production of IL-23 was significantly reduced in LPS-stimulated C57BL/6 DCs after blocking endogenous CCL17/22 with anti-CCL17/22 antibodies (Fig. 5F ). This finding indicates an additional cell-autonomous mode of how DCs modulate IL-23 secretion. In summary, these data demonstrate that production of IL-23 in DCs is CCR4 dependent and regulated via an indirect GM-CSF-dependent manner through CCL17 and CCL22. Finally we asked whether GM-CSF production was required in DCs for EAE development, and used GM-CSF −/− DCs for intracerebral inoculation in this model. As shown in Fig. 5G , GM-CSF −/− DCs failed to induce EAE in CCR4 −/− mice. Together, these findings suggest that CCR4-expressing DCs are critical for the development of EAE via GM-CSF-dependent IL-23 production in these cells.
Discussion
In this study we identified DCs as the relevant cell type mediating CCR4-dependent effects in the development of EAE. Our results demonstrated that CCR4 −/− mice not only exhibited an attenuated clinical course of EAE upon MOG immunization, but were also resistant to EAE induction following transfer of encephalitogenic WT lymphocytes. The expression of CCR4 only in myeloid-derived cells in a BM-chimeric model and the intracerebral injection of CCR4 + DCs was required for EAE development and defined CCR4 + DCs as key mediators of EAE in this model. We showed that CCR4 −/− DCs displayed a defect in the GM-CSF-dependent production of IL-23, and that both cytokines are required to be secreted by DCs for development of EAE in this model. To date, only a few studies have characterized myeloid cellexpressed CCRs as susceptibility factors associated with EAE. In this regard, CCR2 has been shown to affect EAE pathogenesis based on observations that CCR2 −/− mice were resistant to EAE, although this effect was dependent on the genetic background of the mice (34) (35) (36) . Recent studies have unraveled the mechanism of disease resistance in CCR2 −/− animals by demonstrating a disease-promoting role of CCR2 + Ly-6C high monocytes during induction of EAE (37) . During the preparation of this manuscript, it was further suggested that a reduction in the numbers of (TNF-producing) inflammatory macrophages observed in CNS, spleen, and LN were causative for enhanced EAE resistance in CCR4 −/− mice (38) . Our data, however, indicate that equal numbers of myeloid cells (including inflammatory macrophages) are present in the peripheral blood of WT or CCR4 −/− mice at various disease stages. In accordance with this previous study we identified reduced numbers of CNS-immigrating myeloid cells in CCR4 −/− mice at peak disease. Also, CCR4 expression in myeloid cells but not in lymphocytes was shown to be critical in EAE development. Here we demonstrate a functional role for CCR4 expressed by DCs, but not by macrophages, in mediating EAE pathogenesis. Highest CCR4 mRNA expression in DCs suggested these myeloid cells as promising candidates that mediate CCR4 effects in EAE development. The fact that intracerebral reconstitution using CCR4 + DCs (but not CCR4 + macrophages) induced EAE in CCR4 −/− mice defined these cells as relevant in CCR4-mediated development of CNS autoimmunity.
Earlier studies showed that the presence and function of DCs in the CNS correlates with EAE severity (6, 8) . These professional APCs have been suggested to participate in restimulation of myelin-specific CD4 + T cells in the CNS (5, 7, 39, 40) .
The identification of equal numbers of DCs in the CCR4
−/− and WT CNS at the onset of disease suggested no major differences in CNS migration, but cannot fully exclude that migratory deficits of CCR4 −/− DCs occur at a later time point during disease development. However, we could not detect a defect in basic DC functions in CCR4 −/− DCs, e.g., migration from peripheral sites, expression of costimulator molecules, and antigen presentation. The fact that functional encephalitogenic T cells were induced in CCR4 −/− mice further demonstrates the capacity of CCR4
−/− DCs in activating naive T cells.
Importantly, we could demonstrate that CCR4 −/− DCs were deficient in IL-23 production and maintaining (long-term) T H -17 cell cultures. We further showed that CCR4 regulated IL-23 production in DCs via an indirect mode. CCL17/CCL22 up-regulated CCR4-dependent production of GM-CSF in DCs, which in turn induced IL-23 secretion in CCR4 + DCs in an auto or paracrine manner. The relevance of the IL-23/IL-17 axis in the pathogenesis of CNS autoimmunity is well established. For example, p19-deficient mice (one of the heterodimeric IL-23 subunits) failed to develop EAE after MOG immunization (30, 31) . The critical role of IL-23 in mediating EAE pathology was ascribed to its ability to cause an accumulation of myelin-specific T H -17 cells in the CNS rather than expanding autoreactive cells in the periphery (32) . Recent studies have further defined the impact of GM-CSF in this process because it can act to stimulate DC production of IL-23 during autoimmune responses. However, GM-CSF-mediated effects on IL-23 production by DCs have been attributed before to T cells (33) . Two recent studies demonstrated that T-cell-derived GM-CSF sustained neuroinflammation via myeloid cells that infiltrated the CNS (41, 42) . Our studies now extend these data and define that GM-CSF production in DCs is regulated by CCR4 and is required for the development of EAE through modulation of IL-23. The findings that GM-CSF −/− DCs produced significantly lower levels of IL-23 compared with C57BL/6 controls provide further evidence that IL-23 production in DCs is also propagated by a GM-CSF-dependent autocrine mechanism. We further showed that CCR4 −/− mice exhibited (i) reduced GM-CSF and IL-23 protein levels in the CNS and (ii) a defect in GM-CSF and IL-23 production in CNS-immigrating mice per group; P < 0.05, day 12; P < 0.01, day 14; P < 0.001, days [16] [17] [18] . Data are representative of at least two independent experiments.
DCs after MOG immunization. The intraspinal reconstitution with IL-23 induced development of EAE in CCR4 −/− mice. DC-derived IL-23 or GM-CSF were further shown to be major components in disease progression, because the intracerebral inoculation using IL-23 −/− or GM-CSF −/− DCs failed to induced EAE in CCR4 −/− mice in contrast to WT DCs. Of note, exogenously added CCL17/22 induced the production of only small amounts of GM-CSF, even by CCR4 + DCs in in vitro cultures, whereas high levels of exogenous GM-CSF significantly enhanced IL-23 production by DCs. This finding suggests that other cells (e.g., monocytes) contribute to IL-23 production by DCs in this model; however, the small amounts of GM-CSF produced by DCs are absolutely required for EAE development.
Our findings suggest that CCR4-mediated signals confer a positive feedback loop during the development of EAE. That is, myeloid cells (like DCs or macrophages) expressing CCR4 receptors are also capable of producing CCL17 and CCL22, thereby perpetuating myeloid cell infiltration (16, 22) . Furthermore, this study identified CCR4 + DCs as key cellular components required for the initiation of the recruitment process. Defective production of CCR4 ligands by macrophages and DCs in the absence of CCR4 could alternatively cause reduced bystander recruitment, leading to diminished numbers of local encephalitogenic T cells and, in consequence, reduced numbers of macrophages and DCs. Recently, Dogan et al. (43) showed that CCL22 played a regulatory role in EAE by mediating inflammatory macrophage accumulation in the CNS and affecting effector functions. Consistent with this hypothesis, a defect in CCL22 production by CCR4 −/− APCs was found following stimulation with TLR ligands (26) . The increased numbers of myeloid cells in the CNS might represent the critical mass needed for the generation of the appropriate cytokines and chemokines (including GM-CSF-mediated regulation of IL-23 in DCs) required for the maintenance of encephalitogenic T cells in the CNS.
In summary, our findings show an essential role for CCR4 expressed by DCs for EAE pathogenesis. Therefore, targeting DC-specific CCR4 signaling pathways is a promising therapeutic approach to the treatment of CNS autoimmunity.
Materials and Methods
